Selective use of radioactive iodine in intermediate-risk papillary thyroid cancer.
暂无分享,去创建一个
J. Shah | I. Ganly | Snehal G. Patel | R. Tuttle | A. Shaha | I. Nixon | F. Palmer | M. Dilorenzo | S. Patel
[1] M. Ringel,et al. The Role of Radioactive Iodine in Salivary Gland Dysfunction , 2000, Ear, nose, & throat journal.
[2] J. Tward,et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.
[3] F. Jegoux,et al. Pattern of lateral neck metastases in N0 papillary thyroid carcinoma , 2011, BMC Cancer.
[4] P. Hall,et al. Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.
[5] S. Mandel,et al. Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.
[6] D. Elkins,et al. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. , 2004, Thyroid : official journal of the American Thyroid Association.
[7] C. Begg,et al. Prognostic factors in differentiated carcinoma of the thyroid gland. , 1992, American journal of surgery.
[8] A. Sanabria,et al. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer , 2011, Head & neck.
[9] J. Griggs,et al. Use of radioactive iodine for thyroid cancer. , 2011, JAMA.
[10] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[11] I. Ganly,et al. Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy , 2011, Cancer.
[12] B. Malpani,et al. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. , 1996, International journal of radiation oncology, biology, physics.
[13] J. Watkinson,et al. The British Thyroid Association guidelines for the management of thyroid cancer in adults , 2004, Nuclear medicine communications.
[14] S. Straus,et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.
[15] W. Wiersinga,et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.
[16] E. Choi,et al. Predictive Factors For Ipsilateral or Contralateral Central Lymph Node Metastasis in Unilateral Papillary Thyroid Carcinoma , 2009, Annals of surgery.
[17] C. Silver,et al. Paratracheal node dissection for well-differentiated cancer of the thyroid: indications, technique and results. , 2008, Auris, nasus, larynx.
[18] J. Shah,et al. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: A matched‐pair analysis , 1996, Head & neck.
[19] S. Larson,et al. Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation , 2009, Journal of Nuclear Medicine.
[20] L. Kowalski,et al. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. , 2009, Archives of otolaryngology--head & neck surgery.
[21] C. Kirsch,et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.